Medtronic plc (MDT)

Total return at 5 years: 9.5%/year = 6.6% appreciation + 2.9% dividend. The target price ($126) is ex-dividend; the $15 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $164 · Multiples $115) exceeds the market price ($92).

Today — fairly valued: at $92 trades ~19.9% below its value discounted to today (~$115); the discount is positive but does not reach the margin of safety we require (≥38%).

At 5 years — En valor: the target price ($126) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.

The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$73.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($92) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-6.9%/year) than we project (5.7%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$5.1 bn of owner earnings in year 5 (vs ~$9.7 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Diversified medical technology. The model is built at the enterprise level: the multiple is applied to after-tax operating profit, which is pre-interest, so cash and short-term investments (US$8,819 million) and debt (US$24,676 million) enter the bridge and funding is charged once. The present-value lens, by contrast, runs at the equity level, on the adjusted earnings the company itself declares: that is why its net cash is zero and there is no bridge there. The model's margin series is on an adjusted rather than GAAP basis, and that matters when reading it: as of July 31, 2026 adjusted operating profit for the trailing window is US$9,155 million on revenue of US$37,541 million, or 24.4%, practically identical to the 24.35% the model already carried — the GAAP margin for the same window is 18.1%, and the gap is amortization of acquisition-related intangibles, restructuring and litigation charges. Year 0 = trailing twelve months ended July 31, 2026, incorporated from the fiscal first quarter 2027 earnings 8-K. Year 1 falls from +5.0% to +4.5% even though the trailing window grew +9.8%, and the reason is a single one: the fiscal first quarter of 2027 had an extra fiscal week that the company itself quantifies at ~US$570 million of organic growth. That quarter sits inside year 0 and outside the +1y window, which moreover laps against it with one week less. With the raised fiscal 2027 guidance —organic growth of 7.25% to 7.75%, a 50 basis point increase, and adjusted diluted earnings per share of US$5.94 to 6.00— the three remaining quarters of the year grow ~5.6% over their comparable, and on top of those the window adds a fiscal first quarter 2028 of thirteen weeks against fourteen: the result is ~+4.5%. Year 2 rebounds to ~5.3% as it clears that lapping effect (the rebound exception to the deceleration rule, declared here) and from there decelerates toward +4.4% by year 5. The second anchor of the guidance sets the margin: the US$5.97 per share midpoint on ~1,285 million shares implies adjusted earnings of ~US$7,671 million, that is an adjusted net margin of ~19.5%, slightly below the 19.6% of the trailing window, because the company guides ~US$250 million of new tariffs for fiscal 2027 against ~US$185 million in fiscal 2026. That is why the year-1 margin does not expand and only recovers toward ~20.5% by year 5. The base exit multiple (17.5x) sits in the lower part of the quality medical technology band (16x-22x), disciplined by a return on invested capital of 8.1%, still below the 10% hurdle. The incremental return is not published for this window: invested capital fell from US$68.2 billion to US$66.1 billion with the quarter's debt repayment, and a ratio with a contracting denominator does not measure compounding. Cash does not accumulate and no share path is modeled: the diluted count barely fell from 1,287.1 to 1,285.1 million over the year, well below the materiality threshold.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $126 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $92, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $126 in 5 years plus $15 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $115. Against the current market price ($92), the margin of safety is 19.9% (trades below the maximum → there is margin) and the total return at that price would be 9.5% annually.

• Multiple vs. the band. Trades at ~18× adjusted after-tax operating income — below the quality med-tech band (16-22×).
• Comparables. The discount versus diversified med-tech peers is marked; it is partly justified by the weaker return on invested capital and new tariffs, but not entirely.
• Margin of safety. 5-year base case ~$126 vs. price ~$92 → total return +9%/year. It trades close to intrinsic value, far from the required margin of safety.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✕ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (137%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• ROIC vs. the 10% bar. Aggregate return on invested capital ~7% — below the bar, weighed down by goodwill inherited from past acquisitions (~$42.6bn on the balance sheet).
• Margin and stability. GAAP operating margin ~17.8% (TTM), pressured by tariffs and disclosed charges; non-GAAP adjusted earnings (~19.6% margin) are more representative of the underlying economics.
• Cash quality. Reported free cash flow (~$5.4bn) is consistent with the company's reported adjusted earnings (owner earnings ~$7.1bn) — earnings are largely backed by real cash.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

The MD&A does not break down each segment's growth into volume vs. price/mix — it only states, qualitatively, that the increase came from the underlying business across most lines plus 'foreign currency fluctuation impacts' across the four segments, without quantifying the currency component. Cardiovascular is the growth engine (39% of revenue, +12%, with new ablation platforms); Diabetes/MiniMed (9%, +13%) is being spun off (Medtronic retains ~90% after the partial IPO in March 2026) and will stop being consolidated in the future.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (31-jul-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real, not nominal. Reported growth in the latest year (+8.4%) includes a currency tailwind and a one-time adjustment in Italy, neither quantified by the company — the real pace of the three-year trajectory is more moderate (~5%).
• Growth engine. Cardiovascular (39% of revenue, +12%) is the growth engine, with new ablation platforms; Neuroscience and Medical Surgical grow at a more moderate pace (+4% and +5%).
• Deceleration and cycle. Adjusted earnings per share grew just +0.6% year over year despite the increase in sales, pressured by new tariffs — a sign that revenue growth did not translate into earnings growth this year.

• Relevant in 10 years (recurrence). Implantable medical devices and capital equipment with recurring replacement consumables — demand tied to demographics and procedure volume, not fashion. High recurrence.
• Pricing power. Mixed: recent growth comes mostly from volume and a currency tailwind, not from strong, sustained price/mix; hospital buyer consolidation limits room to maneuver.
• Moat and its direction. Wide moat (patents, scale, regulatory barriers) and stable, with no clear signs of widening or structural erosion.
• Capital cycle. A sector with high regulatory barriers (FDA approvals, European regulation) that limit new capital entry; the competitive risk is consolidation among established rivals, not new entrants.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)9.4x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 137% of ROIC
• ✕Value creation (ROIC − 10% bar)-2pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.6x — no over-investment
• –Float / working capitalNeutral WC
• ✓Dilution (SBC % of revenue + shares)SBC 1.3% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Net debt ~$18.7bn — manageable, with access to the investment-grade debt market (recent euro-denominated issuances).
• Coverage and cash. Free cash flow (~$5.4bn) comfortably covers the dividend (~$3.6bn); additional liquidity of ~$9.2bn between cash and short-term investments.
• Tax litigation. The transfer-pricing litigation with the U.S. tax authority (fiscal years 2005-2006) remains unresolved nearly two decades later — a contingent liability not recognized on the balance sheet.

How cash comes in and how it is deployed. In green, the business's own cash (the owner-FCF it generates and reinvests); in gray, the float and credit — customer and funding money, which is not the shareholder's.

The dividend is the capital allocation priority (52% of capital deployed in the latest fiscal year, with 49 consecutive years of increases); capex runs at around 27%; buybacks (15%) fell sharply versus the prior year; M&A is marginal (6%, one-off acquisitions). The ongoing Diabetes/MiniMed spin-off is the period's most significant capital allocation decision.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Skin in the game. Directors and executive officers hold 0.27% as a group (DEF 14A of August 2026) — a low stake, typical for a company of this scale; the largest holders are index managers (Vanguard 9.1%, BlackRock 8.7%).
• Capital allocation. The dividend (52% of capital deployed, 49 years of increases) is the priority; buybacks fell sharply; M&A is marginal. The Diabetes/MiniMed spin-off is the period's most significant structural decision.
• Integrity / normalization. Detailed GAAP-to-non-GAAP reconciliation, consistent year over year; the company transparently discloses restructuring, litigation and tariff charges.

• New, quantified tariffs (~$185 million in the latest fiscal year, with further guidance of ~$250 million for the next) pressure the margin just as the market was expecting a recovery — a source of discount that is real, not merely perceived.
• The ongoing Diabetes/MiniMed spin-off (~90% retained after the partial IPO) adds execution uncertainty with no definitive closing date.
• The long-running transfer-pricing litigation with the U.S. tax authority (fiscal years 2005-2006) remains unresolved nearly two decades later, after being remanded again to the tax court in September 2025 — a legal overhang that weighs on the narrative even though it is not quantified.

There is a genuine combination of factors: new, quantified costs (tariffs), execution uncertainty (the Diabetes spin-off) and a long-standing legal overhang (the tax litigation). This is not a case of exaggerated perception without basis — the discount versus peers such as Stryker or Abbott is partly explained by a return on invested capital (~7% at the aggregate level) below the 10% bar, weighed down by goodwill inherited from past acquisitions.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at ~0%/year (+1% total): the margin of safety protects the downside. The bull (+14%/year, +96% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Tariffs. ~$185 million of impact in the latest fiscal year, with further guidance of ~$250 million for the next — a new and still-evolving structural cost.
• Tax litigation (Puerto Rico). Nearly two decades unresolved; remanded again to the tax court in September 2025. An adverse ruling would, per the company's own disclosure, have a material impact.
• Diabetes/MiniMed spin-off. The company retains ~90% after the partial IPO in March 2026; the full spin-off is expected in the next fiscal year but with no guaranteed conditions or timeline.
• Regulatory quality / product litigation. Structural risk for any implantable medical device manufacturer: recalls, safety alerts and product liability claims, with the European medical device regulation extending through 2027-2028.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: ROIC 8% does not clear the 10% bar.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 6% at a multiple/growth of 3.1 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 6% (EBIT/EV) + ROIC 8% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -7% vs our 6%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -3%/yr, bull-scenario ceiling +12%/yr over 5y: reasonable asymmetry, without an ample cushion.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, stable; sources: switching costs, intangibles, efficient scale, cost advantage → passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -7%, within what we project (6%) — the story squares with the numbers.